A mouse study reveals a connection between dementia risk and cold frequency.

Published Date: 05 Apr 2023

Being ill frequently may slow down brain aging and raise the risk of dementia and other forms of cognitive decline.

Read Full News

Latest News

Linking Exercise to Dopamine and Motor Performance in Parkinson Disease Marco Meglio

Margaret Rice, PhD, a professor in the Departments of Neurosurgery and Neuroscience at NYU Grossman School of Medicine, provided answers on recently published preclinical research relating aerobic exercise to dopamine release and coordination in PD.

NeurologyLive® Year in Review 2025: Top Interviews on the AI Takeover Isabella Ciccone, MPH

As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews on the latest advances and use of artificial intelligence in neurology care.

NeuroVoices: David A. Hafler, MD, FANA, on Understanding MS as an Autoimmune and Neurodegenerative Disease Isabella Ciccone, MPH, David A. Hafler, MD, FANA

At ECTRIMS 2025, the William S. and Lois Stiles Edgerly Professor of Neurology at Yale School of Medicine discussed evolving insights into the disease pathogenesis of multiple sclerosis.

NeurologyLive® Year in Review 2025: Top trending Migraine Trials NeurologyLive® Staff

As part of NeurologyLive®'s Year in Review 2025, we've compiled some of the top trending migraine trials.

NeurologyLive® Year in Review 2025: Spotlighting SAP Collaborations Isabella Ciccone, MPH

As part of NeurologyLive®'s Year in Review, take a look at our top collaborative interviews with the Strategic Alliance Partnership program in 2025.

NeurologyLive® Year in Review 2025: Most Impactful FDA Decisions Isabella Ciccone, MPH

These were the most impactful FDA approval stories that were part of our coverage in 2025, brought to you as part of NeurologyLive's Year in Review.

Todays Updates

Previewing Expected FDA Decisions in Neurology for 2026 Marco Meglio

Explore anticipated FDA decisions on groundbreaking neurology drugs in 2026, shaping treatment options for various neurologic conditions.

NeurologyLive® Year in Review 2025: What Trials Could Reshape Alzheimer Care? Isabella Ciccone, MPH

As part of NeurologyLive®'s Year in Review, take a look at some of the top ongoing clinical trials in Alzheimer disease and dementia that may impact care.

NeurologyLive® Friday 5 — January 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 2, 2026.

Psychiatry in 2025: Year in Review

Psychiatry in 2025: Year in Review

Gastroenterology in 2025: Year in Review

Gastroenterology in 2025: Year in Review

Weight-Adjusted Waist Index Predicts Cardiovascular Risk in Patients with T2D

Weight-Adjusted Waist Index Predicts Cardiovascular Risk in Patients with T2D

Todays Updates

Previewing Expected FDA Decisions in Neurology for 2026 Marco Meglio

Explore anticipated FDA decisions on groundbreaking neurology drugs in 2026, shaping treatment options for various neurologic conditions.

NeurologyLive® Year in Review 2025: What Trials Could Reshape Alzheimer Care? Isabella Ciccone, MPH

As part of NeurologyLive®'s Year in Review, take a look at some of the top ongoing clinical trials in Alzheimer disease and dementia that may impact care.

NeurologyLive® Friday 5 — January 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 2, 2026.

Psychiatry in 2025: Year in Review

Psychiatry in 2025: Year in Review

Gastroenterology in 2025: Year in Review

Gastroenterology in 2025: Year in Review

Weight-Adjusted Waist Index Predicts Cardiovascular Risk in Patients with T2D

Weight-Adjusted Waist Index Predicts Cardiovascular Risk in Patients with T2D

Latest News

Margaret Rice, PhD, a professor in the Departments of Neurosurgery and Neuroscience at NYU Grossman School of Medicine, provided answers on recently published preclinical research relating aerobic exercise to dopamine release and coordination in PD.

As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews on the latest advances and use of artificial intelligence in neurology care.

At ECTRIMS 2025, the William S. and Lois Stiles Edgerly Professor of Neurology at Yale School of Medicine discussed evolving insights into the disease pathogenesis of multiple sclerosis.

As part of NeurologyLive®'s Year in Review 2025, we've compiled some of the top trending migraine trials.

As part of NeurologyLive®'s Year in Review, take a look at our top collaborative interviews with the Strategic Alliance Partnership program in 2025.

These were the most impactful FDA approval stories that were part of our coverage in 2025, brought to you as part of NeurologyLive's Year in Review.

News All Time

From the Field: Neurologist-Written Insights From 2025 NeurologyLive® Staff

A look back at clinician-led features from 2025 that examine the questions, data, and decisions shaping neurologic care.

NeurologyLive® Year in Review 2025: Notable Trials Beginning This Year NeurologyLive® Staff

As part of NeurologyLive®'s Year in Review 2025, we've compiled some notable trials that began in 2025.

NeurologyLive® Year in Review 2025: Top Interviews in Multiple Sclerosis Care NeurologyLive® Staff

As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews regarding multiple sclerosis in 2025.

NeuroVoices: Joseph Sullivan, MD, on ETX101 Gene Regulation Therapy and Early POLARIS Findings in Dravet Syndrome Marco Meglio

The director of the Pediatric Epilepsy Center at UCSF reviewed recently presented interim phase 1/2 data for ETX101, a one-time AAV9 gene regulation therapy aiming to increase SCN1A expression in inhibitory interneurons in Dravet syndrome.

What’s All the Buzz? Trending Topics and Phrases of Neurology in 2025 Marco Meglio

Explore the transformative buzzwords in neurology for 2025, highlighting advancements in AI, gene therapy, personalized treatment, and neuroplasticity.

Adults with Developmental and Epileptic Encephalopathies in the Precision Treatment Era Danielle Andrade, MD, MSc

Explore the evolving landscape of developmental and epileptic encephalopathies in adults, highlighting precision therapies and the need for accurate diagnoses.

Remyelinating Agent PIPE-307 Falls Short in Phase 2 Trial of Relapsing Multiple Sclerosis Marco Meglio

Continuem's PIPE-307 trial for relapsing-remitting multiple sclerosis failed to meet primary goals, yet the company remains committed to exploring future therapies.

This Week on NeurologyLive® — December 22, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Brain-Penetrant Molecule GT-02287 Demonstrates Reversal of Glucosylsphinogosine in Parkinson Disease Marco Meglio

Gain Therapeutics advances Parkinson's treatment with GT 2287, showcasing promising safety and tolerability in ongoing trials. Discover the latest findings.

CAPN2-Targeting Agent AMX0114 Shows Safe Profile in Phase 1 LUMINA Trial of ALS Marco Meglio

New findings from the LUMINA trial reveal AMX0114's safety in ALS patients, paving the way for further research and potential treatment advancements.

NeurologyLive® Brain Games: December 21, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on neuromodulation for Parkinson disease!

Repositioning GLP-1 Drugs for Neurologic Disease: Evidence, Advances, and Outlook Marco Meglio

GLP-1 research in neurology is on the rise, with several pivotal studies lending insights into their role.

Frontlines with Frontera: Using Artificial Intelligence to Rethink Seizure Management in the Neuro ICU Jennifer Frontera, MD, Sahar Zafar, MD, MBBS

Frontlines with Frontera, a podcast hosted by neurointensivist Jennifer Frontera, MD, brings you an exclusive interview with Sahar Zafar, MD, MBBS. [LISTEN TIME: 30 minutes]

NeurologyLive® Friday 5 — December 19, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 19, 2025.

FDA Expands Indication for n‐Butyl Cyanoacrylate in Chronic Subdural Hematoma Isabella Ciccone, MPH

The expanded indication brings n-butyl cyanoacrylate’s established performance into the treatment of chronic subdural hematoma, a condition for which traditional surgical interventions may not always be suitable or effective.

Phase 3b STRENGTH Trial Provides Greater Support for Intrathecal SMA Gene Therapy Marco Meglio

Phase 3b study revealed Itvisma's safety and efficacy in treating spinal muscular atrophy, showing modest motor function improvements in patients previously on other therapies.

Recommended News For You

Recurrent UTIs impact eGFR in children with vesicoureteral reflux

Study Finds Actionable Mutations in Brain Mets of Breast Cancer Patients

Ignoring Colonoscopy Advice; Dry Mouth Acupuncture; Inflamed Tongue, Then Cancer.

UK study evaluates effectiveness of cancer diagnosis pathway for patients with non-specific symptoms

How Social Determinants of Health Are Linked to Outcomes in Multiple Myeloma

Drugmaker Pulls Trodelvy's Bladder Cancer Approval

DNA origami offers more accurate imaging in the fight against pancreatic cancer

Recommended Articles For You

How is Digital Innovation Revolutionizing Gynecologic Oncology Treatment and Patient Engagement? 

Understanding the Importance of Red Cell Distribution Width (RDW) in Blood Tests  

Effective Management Strategies for Sickle Cell Crisis: Insights from Medical Experts 

Uncovering the Reality of Colon Cancer: A Look at Real Images 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

For relapsed or resistant DLBCL, odronextamab produced positive results.

2.

It Is Cancer in Kate Middleton.

3.

Hospitalized Kate Middleton; Sen. Paul Demands That Fauci Go To Prison; COVID Returns to Class.

4.

I Understand Why Defense Secretary Austin Kept His Prostate Cancer Quiet.

5.

U.S. Nurse Found Dead; Harvey Weinstein's Cancer; Creepy Source of Ear Pain

1.

AI-Driven Chemotherapy: Transforming Cancer Care with Precision and Efficiency

2.

Lymphomatoid Papulosis: What You Need to Know

3.

KEYNOTE-826: Optimizing Outcomes in Persistent, Recurrent, or Metastatic Cervical Cancer

4.

Cemiplimab: A Revolutionary Drug For Treating Cancer

5.

Colon Cancer Staging: What You Need to Know

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI

2.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I

3.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part V

4.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion

5.

CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot